AIDS Research Center, Institute of Pathogen Biology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
PLoS One. 2011;6(5):e19863. doi: 10.1371/journal.pone.0019863. Epub 2011 May 20.
Pandemic influenza represents a major threat to global health. Vaccination is the most economic and effective strategy to control influenza pandemic. Conventional vaccine approach, despite being effective, has a number of major deficiencies including limited range of protection, total dependence on embryonated eggs for production, and time consuming for vaccine production. There is an urgent need to develop novel vaccine strategies to overcome these deficiencies.
METHODOLOGY/PRINCIPAL FINDINGS: The major objective of this work was to develop a novel vaccine strategy combining recombinant haemagglutinin (HA) protein and a master cell (MC) activator C48/80 for intranasal immunization. We demonstrated in BALB/c mice that MC activator C48/80 had strong adjuvant activity when co-administered with recombinant HA protein intranasally. Vaccination with C48/80 significantly increased the serum IgG and mucosal surface IgA antibody responses against HA protein. Such increases correlated with stronger and durable neutralizing antibody activities, offering protection to vaccinated animals from disease progression after challenge with lethal dose of A/California/04/2009 live virus. Furthermore, protected animals demonstrated significant reduction in lung virus titers, minimal structural alteration in lung tissues as well as higher and balanced production of Th1 and Th2 cytokines in the stimulated splenocytes when compared to those without C48/80.
CONCLUSIONS/SIGNIFICANCE: The present study demonstrates that the novel vaccine approach of combining recombinant HA and mucosal adjuvant C48/80 is safe and effective in eliciting protective immunity in mice. Future studies on the mechanism of action of C48/80 and potential combination with other vaccine strategies such as prime and boost approach may help to induce even more potent and broad immune responses against viruses from various clades.
大流行性流感对全球健康构成重大威胁。疫苗接种是控制流感大流行的最经济有效的策略。尽管常规疫苗方法有效,但存在许多重大缺陷,包括保护范围有限、完全依赖鸡胚生产疫苗以及疫苗生产耗时。因此,迫切需要开发新的疫苗策略来克服这些缺陷。
方法/主要发现:这项工作的主要目标是开发一种新的疫苗策略,将重组血凝素(HA)蛋白与主细胞(MC)激活剂 C48/80 结合,用于鼻腔内免疫接种。我们在 BALB/c 小鼠中证明,MC 激活剂 C48/80 与重组 HA 蛋白鼻内共给药时具有很强的佐剂活性。用 C48/80 接种疫苗可显著增加针对 HA 蛋白的血清 IgG 和粘膜表面 IgA 抗体反应。这种增加与更强和更持久的中和抗体活性相关,为接种动物提供了保护,使其免受致命剂量 A/加利福尼亚/04/2009 活病毒攻击后的疾病进展。此外,与未使用 C48/80 的动物相比,受保护的动物的肺部病毒滴度显著降低,肺部组织的结构改变最小,以及刺激脾细胞中 Th1 和 Th2 细胞因子的产生更高且更平衡。
结论/意义:本研究表明,将重组 HA 和粘膜佐剂 C48/80 结合的新型疫苗方法在诱导小鼠产生保护性免疫方面是安全有效的。未来关于 C48/80 作用机制的研究以及与其他疫苗策略(如初次免疫和加强免疫)的潜在结合可能有助于诱导针对来自不同进化枝的病毒的更有效和广泛的免疫反应。